New strategy tested to overcome resistance to melanoma immunotherapy
NCT ID NCT04225390
Summary
This study tested a two-step approach for patients with advanced melanoma that did not respond to standard immunotherapy. First, patients received a chemotherapy drug (DTIC). Then, they tried immunotherapy again. The goal was to see if the chemotherapy could 'reset' the tumor and make it responsive to the immunotherapy it had previously resisted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital
Erlangen, Bavaria, 91054, Germany
Conditions
Explore the condition pages connected to this study.